Inventiva (IVA) Cash & Current Investments (2018 - 2025)
Inventiva (IVA) recorded quarterly Cash & Current Investments of $268.7 million in Q4 2025, up 22.2% quarter-over-quarter from $219.9 million in Q2 2025, and up 160.33% on a YoY basis from $103.2 million in Q4 2024.
Inventiva (IVA) Cash & Current Investments (2018 - 2025) Analysis & Trends
Inventiva's Cash & Current Investments history runs 8 years deep, the most recent figure standing at $268.7 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 160.33% year-over-year to $268.7 million; the TTM figure through Dec 2025 stood at $268.7 million (up 160.33% YoY), while the FY2025 annual figure was $268.7 million, up 160.33% from the prior year.
- Cash & Current Investments was $268.7 million for Q4 2025 at Inventiva, up from $219.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $268.7 million in Q4 2025 to a low of $9.7 million in Q4 2023.
- Historically, Cash & Current Investments has averaged $107.0 million across 5 years, with a median of $99.0 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments slumped 88.99% in 2023, then soared 959.53% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $99.0 million in 2021, then fell by 10.63% to $88.5 million in 2022, then plunged by 88.99% to $9.7 million in 2023, then surged by 959.53% to $103.2 million in 2024, then soared by 160.33% to $268.7 million in 2025.
- The last three Cash & Current Investments figures came in at $268.7 million (Q4 2025), $219.9 million (Q2 2025), and $103.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inventiva | 8.52 Mn | -260.21 Mn | - | 268.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 268.73 Mn |
| Jun 30, 2025 | 219.92 Mn |
| Dec 31, 2024 | 103.23 Mn |
| Jun 30, 2024 | 43.60 Mn |
| Dec 31, 2023 | 9.74 Mn |
| Oct 11, 2023 | 12.54 Mn |
| Jun 30, 2023 | 105.20 Mn |
| Dec 31, 2022 | 88.49 Mn |
| Sep 22, 2022 | 90.31 Mn |
| Jun 30, 2022 | 92.36 Mn |
| Dec 31, 2021 | 99.01 Mn |
| Jun 30, 2021 | 127.28 Mn |
| Mar 31, 2021 | 130.04 Mn |
| Dec 31, 2020 | 126.01 Mn |
| Jun 30, 2020 | 57.58 Mn |
| Mar 31, 2020 | 51.77 Mn |
| Dec 31, 2019 | 39.67 Mn |
| Dec 31, 2018 | 64.71 Mn |